Phase 3 Readout
NVO: Phase 3 Topline: A Study Investigating Clinical Comparability of Two Formulations of Oral Semaglutide in Japanese Par
August 4, 2026. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- August 4, 2026
- Company
- Novo Nordisk A/S (NVO)
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
Phase 3 Readout
Phase 3 Topline: A Study Investigating Clinical Comparability of Two Formulations of Oral Semaglutide in Japanese Par
- Company
- Novo Nordisk A/S (NVO)
- Indication
- Type 2 Diabetes
Other upcoming events for NVO
Phase 3 ReadoutPhase 3 Topline: Efficacy and Safety of Cagrilintide s.c. 2.4 Milligram (mg) in Combination With Semaglutide Subcutan
Phase 3 ReadoutPhase 3 Topline: Long-term Safety and Efficacy of Semaglutide s.c. Once-weekly on Weight Management in Children and A
Phase 3 ReadoutPhase 3 Topline: ARTEMIS - Effects of Ziltivekimab Versus Placebo on Cardiovascular Outcomes in Patients With Acute M